ReviewFrontiers in pharmacology2025
PLGA-based nanoparticles in colorectal cancer immunotherapy: current concepts and future perspectives.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Heating the Cold: Overcoming Immunotherapy Resistance in Microsatellite-Stable Colorectal Cancer: A Systematic Review.Molecules (Basel, Switzerland) · 2026Pooled it
- Unveiling the potential of solid lipid nanoparticles of apigenin-Cu(II) coordinated nanocomplex in colon cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Nanoparticle Platforms in Cancer Immunotherapy: A Critical Comparative Review of PLGA, Mesoporous Silica, Magnetic Nanoparticles, and Covalent Organic Frameworks.Pharmaceutics · 2026Review
- From LNPs to hybrid nanocarriers: development, challenges and redesign of non-viral gene delivery.Journal of nanobiotechnology · 2026Review
- Structural and functional evolution of IL-1 targeting: From systemic neutralization to bioengineered nanotherapies.Materials today. Bio · 2026Review
- Electrosprayed PLGA Nanoparticles for Dual Drug Delivery: Design, Optimization and Applications.Polymers · 2026Review
- Size-Dependent Immunomodulatory Effects of FeMolecules (Basel, Switzerland) · 2026Article
- Duodenal and cutaneous metastases from advanced rectal cancer: a rare case report.Frontiers in oncology · 2026Article
- Decoding the role of exosomes in bladder cancer: focusing on tumor progression and immune microenvironment modulation.Frontiers in oncology · 2026Review
- Nanomedicine delivery systems remodel the immunosuppressive microenvironment of colorectal cancer: synergistic strategies and mechanisms of targeted immune checkpoint inhibitors.Frontiers in immunology · 2026Review
- Natural Polymers Based Biocompatible Nanomedicines for Targeting Colon Cancer: Prospects and Challenges.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) remains a leading cause of cancer mortality, and the benefits of immune checkpoint inhibitors are largely confined to the dMMR/MSI-H minority, underscoring the need to remodel the immunosuppressive tumor microenvironment (TME). Poly (lactic-co-glycolic acid) (PLGA) nanoparticles offer biodegradable, tunable carriers with high payload capacity and amenability to targeting, enabling precise delivery and controlled release of immunomodulators. In CRC, these platforms can enhance antigen capture and presentation, recondition suppressive myeloid networks, and coordinate checkpoint blockade with complementary therapeutics to strengthen antitumor immunity and restrain tumor growth. In this review, we summarize current principles for PLGA nanoparticles-based immunotherapies, emphasizing payload selection, release kinetics, microenvironmental responsiveness, and spatiotemporal targeting in CRC. We also outline translational considerations encompassing safety, pharmacokinetics, manufacturability, and regulatory readiness. Addressing these factors may accelerate clinical deployment of PLGA-enabled strategies and extend the benefits of immunotherapy in CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.